Analysts Set Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Target Price at $5.80

Shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) have earned an average rating of “Moderate Buy” from the six analysts that are presently covering the company, MarketBeat.com reports. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average 12 month target price among analysts that have covered the stock in the last year is $5.17.

Several research analysts have recently issued reports on SGMO shares. Truist Financial dropped their target price on shares of Sangamo Therapeutics from $7.00 to $5.00 and set a “buy” rating on the stock in a research note on Thursday, January 23rd. Royal Bank of Canada reissued a “sector perform” rating and issued a $2.00 target price on shares of Sangamo Therapeutics in a report on Tuesday. HC Wainwright reaffirmed a “buy” rating and set a $10.00 price target on shares of Sangamo Therapeutics in a report on Monday, January 27th. Jefferies Financial Group decreased their target price on Sangamo Therapeutics from $7.00 to $3.00 and set a “buy” rating for the company in a research report on Tuesday, December 31st. Finally, StockNews.com lowered shares of Sangamo Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, December 24th.

Institutional Trading of Sangamo Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Charles Schwab Investment Management Inc. boosted its stake in shares of Sangamo Therapeutics by 5.5% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,103,326 shares of the biopharmaceutical company’s stock worth $956,000 after acquiring an additional 57,125 shares during the last quarter. FMR LLC lifted its position in Sangamo Therapeutics by 16.5% during the third quarter. FMR LLC now owns 544,003 shares of the biopharmaceutical company’s stock valued at $471,000 after purchasing an additional 77,032 shares in the last quarter. State Street Corp grew its holdings in Sangamo Therapeutics by 28.0% during the third quarter. State Street Corp now owns 664,621 shares of the biopharmaceutical company’s stock valued at $576,000 after purchasing an additional 145,400 shares during the period. XTX Topco Ltd increased its position in Sangamo Therapeutics by 167.8% in the third quarter. XTX Topco Ltd now owns 103,716 shares of the biopharmaceutical company’s stock worth $90,000 after buying an additional 64,981 shares in the last quarter. Finally, Geode Capital Management LLC increased its position in Sangamo Therapeutics by 14.6% in the third quarter. Geode Capital Management LLC now owns 2,138,309 shares of the biopharmaceutical company’s stock worth $1,853,000 after buying an additional 272,123 shares in the last quarter. 56.93% of the stock is owned by hedge funds and other institutional investors.

Sangamo Therapeutics Stock Down 16.2 %

SGMO stock opened at $0.85 on Friday. The business has a 50 day moving average of $1.09 and a 200 day moving average of $1.41. The firm has a market cap of $176.54 million, a PE ratio of -1.13 and a beta of 1.49. Sangamo Therapeutics has a twelve month low of $0.30 and a twelve month high of $3.18.

Sangamo Therapeutics (NASDAQ:SGMO) last issued its quarterly earnings results on Monday, March 17th. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of ($0.09) by ($0.02). Sangamo Therapeutics had a negative net margin of 257.87% and a negative return on equity of 264.16%. The company had revenue of $7.55 million for the quarter, compared to the consensus estimate of $11.70 million. On average, research analysts expect that Sangamo Therapeutics will post -0.46 earnings per share for the current fiscal year.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.